138 related articles for article (PubMed ID: 31594835)
1. Role of optimal cytoreduction in patients with dysgerminoma.
Bandala-Jacques A; Estrada-Rivera F; Cantu D; Prada D; Montalvo-Esquivel G; González-Enciso A; Barquet-Munoz SA
Int J Gynecol Cancer; 2019 Nov; 29(9):1405-1410. PubMed ID: 31594835
[TBL] [Abstract][Full Text] [Related]
2. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors.
Turkmen O; Karalok A; Basaran D; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):270-276. PubMed ID: 28085535
[TBL] [Abstract][Full Text] [Related]
3. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
4. Trends in the surgical management of malignant ovarian germcell tumors.
Nasioudis D; Mastroyannis SA; Latif NA; Ko EM
Gynecol Oncol; 2020 Apr; 157(1):89-93. PubMed ID: 32008791
[TBL] [Abstract][Full Text] [Related]
5. Pure dysgerminoma of the ovary: a review of 45 well staged cases.
Ayhan A; Bildirici I; Günalp S; Yuce K
Eur J Gynaecol Oncol; 2000; 21(1):98-101. PubMed ID: 10726633
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
7. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
8. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
Bristow RE; Montz FJ
Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors.
Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Int J Gynecol Cancer; 2019 Mar; 29(3):554-559. PubMed ID: 30700566
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
Li J; Yang W; Wu X
Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
12. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival.
Rajkumar S; Nath R; Lane G; Mehra G; Begum S; Sayasneh A
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():26-31. PubMed ID: 30639953
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
14. [Characteristics of rare ovarian tumors--possibilities of organ preservation].
Grischke EM; Wallwiener D; Bastert G
Zentralbl Gynakol; 1996; 118(6):322-5. PubMed ID: 8768007
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors.
Karalok A; Comert GK; Kilic C; Turkmen O; Kilic F; Basaran D; Boyraz G; Tekin ÖM; Turan T
J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):461-466. PubMed ID: 31228608
[TBL] [Abstract][Full Text] [Related]
18. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
19. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors.
Ertas IE; Taskin S; Goklu R; Bilgin M; Goc G; Yildirim Y; Ortac F
J Obstet Gynaecol Res; 2014 Mar; 40(3):797-805. PubMed ID: 24320102
[TBL] [Abstract][Full Text] [Related]
20. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
